Product Name
FBLN5, Blocking Peptide
Full Product Name
FBLN5 Peptide - middle region
Product Gene Name
FBLN5 blocking peptide
[Similar Products]
Product Synonym Gene Name
EVEC; UP50; ADCL2; ARMD3; DANCE; ARCL1A; FIBL-5[Similar Products]
FBLN5 peptide (MBS3245340) is used for blocking the activity of FBLN5 antibody (MBS3220538)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Sequence
Synthetic peptide located within the following region: MMCVNQNGGY LCIPRTNPVY RGPYSNPYST PYSGPYPAAA PPLSAPNYPT
3D Structure
ModBase 3D Structure for Q9UBX5
Form/Format
Lyophilized powder
Preparation and Storage
Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20 degree C. Avoid repeat freeze-thaw cycles.
Other Notes
Small volumes of FBLN5 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
FBLN5 blocking peptide
The protein encoded by this gene is a secreted, extracellular matrix protein containing an Arg-Gly-Asp (RGD) motif and calcium-binding EGF-like domains. It promotes adhesion of endothelial cells through interaction of integrins and the RGD motif. It is prominently expressed in developing arteries but less so in ***** vessels. However, its expression is reinduced in balloon-injured vessels and atherosclerotic lesions, notably in intimal vascular smooth muscle cells and endothelial cells. Therefore, the protein encoded by this gene may play a role in vascular development and remodeling. Defects in this gene are a cause of autosomal dominant cutis laxa, autosomal recessive cutis laxa type I (CL type I), and age-related macular degeneration type 3 (ARMD3).
Product Categories/Family for FBLN5 blocking peptide
Peptide
Applications Tested/Suitable for FBLN5 blocking peptide
Western Blot (WB)
NCBI/Uniprot data below describe general gene information for FBLN5. It may not necessarily be applicable to this product.
NCBI Accession #
NP_006320.2
[Other Products]
NCBI GenBank Nucleotide #
NM_006329.3
[Other Products]
UniProt Primary Accession #
Q9UBX5
[Other Products]
UniProt Related Accession #
Q9UBX5[Other Products]
NCBI Official Full Name
fibulin-5
NCBI Official Synonym Full Names
fibulin 5
NCBI Official Symbol
FBLN5 [Similar Products]
NCBI Official Synonym Symbols
EVEC; UP50; ADCL2; ARMD3; DANCE; ARCL1A; FIBL-5; HNARMD
[Similar Products]
NCBI Protein Information
fibulin-5
UniProt Protein Name
Fibulin-5
UniProt Synonym Protein Names
Developmental arteries and neural crest EGF-like protein; Dance; Urine p50 protein
UniProt Gene Name
FBLN5 [Similar Products]
UniProt Synonym Gene Names
DANCE; FIBL-5; Dance; UP50 [Similar Products]
UniProt Entry Name
FBLN5_HUMAN
NCBI Summary for FBLN5
The protein encoded by this gene is a secreted, extracellular matrix protein containing an Arg-Gly-Asp (RGD) motif and calcium-binding EGF-like domains. It promotes adhesion of endothelial cells through interaction of integrins and the RGD motif. It is prominently expressed in developing arteries but less so in ***** vessels. However, its expression is reinduced in balloon-injured vessels and atherosclerotic lesions, notably in intimal vascular smooth muscle cells and endothelial cells. Therefore, the protein encoded by this gene may play a role in vascular development and remodeling. Defects in this gene are a cause of autosomal dominant cutis laxa, autosomal recessive cutis laxa type I (CL type I), and age-related macular degeneration type 3 (ARMD3). [provided by RefSeq, Jul 2008]
UniProt Comments for FBLN5
FBLN5: Promotes adhesion of endothelial cells through interaction of integrins and the RGD motif. Could be a vascular ligand for integrin receptors and may play a role in vascular development and remodeling. Defects in FBLN5 are the cause of cutis laxa, autosomal dominant, type 2 (ADCL2). A connective tissue disorder characterized by loose, hyperextensible skin with decreased resilience and elasticity leading to a premature aged appearance. Face, hands, feet, joints, and torso may be differentially affected. Additional variable clinical features are gastrointestinal diverticula, hernia, and genital prolapse. Rare manifestations are pulmonary artery stenosis, aortic aneurysm, bronchiectasis, and emphysema. Defects in FBLN5 are a cause of cutis laxa, autosomal recessive, type 1A (ARCL1A). A connective tissue disorder characterized by loose, hyperextensible skin with decreased resilience and elasticity leading to a premature aged appearance. Face, hands, feet, joints, and torso may be differentially affected. The clinical spectrum of autosomal recessive cutis laxa is highly heterogeneous with respect to organ involvement and severity. Type I autosomal recessive cutis laxa is a specific, life-threatening disorder with organ involvement, lung atelectasis and emphysema, diverticula of the gastrointestinal and genitourinary systems, and vascular anomalies. Associated cranial anomalies, late closure of the fontanel, joint laxity, hip dislocation, and inguinal hernia have been observed but are uncommon. Defects in FBLN5 are the cause of age-related macular degeneration type 3 (ARMD3). ARMD is a multifactorial disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid (known as drusen) that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Belongs to the fibulin family.
Protein type: Secreted, signal peptide; Secreted
Chromosomal Location of Human Ortholog: 14q32.1
Cellular Component: extracellular matrix; extracellular space; proteinaceous extracellular matrix; extracellular region
Molecular Function: protein C-terminus binding; integrin binding; protein binding; protein homodimerization activity; calcium ion binding
Biological Process: elastic fiber assembly; extracellular matrix organization and biogenesis; secretion; cell-matrix adhesion; regulation of cell growth
Disease: Cutis Laxa, Autosomal Dominant 2; Macular Degeneration, Age-related, 3; Cutis Laxa, Autosomal Recessive, Type Ia
Research Articles on FBLN5
1. T mutation of FBLN5; findings confirm a novel subtype of autosomal-dominant Charcot-Marie-Tooth disease due to a mutation in the FBLN5 gene">study reports the first Chinese family with c.1117C>T mutation of FBLN5; findings confirm a novel subtype of autosomal-dominant Charcot-Marie-Tooth disease due to a mutation in the FBLN5 gene
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.